Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438613 | 1.00 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL16827362 | 1.00 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL16848202 | 0.88 | AOC3 (0.61) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL12870758 | 0.86 | AOC3 (0.58) | AOC3PKMNPC1RAB9AMAPK14 | |
| SCHEMBL16848201 | 0.86 | AOC3 (0.49) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL16848254 | 0.86 | NOX4 (0.51) | AOC3PKMNPC1RAB9AMAPK14 | |
| SCHEMBL16848252 | 0.86 | AOC3 (0.48) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL16848248 | 0.85 | AOC3 (0.48) | PDE4APDE4BPDE4CPDE4DAOC3 | |
| SCHEMBL16827495 | 0.85 | AOC3 (0.50) | AOC3PKMNPC1RAB9A | |
| SCHEMBL16848253 | 0.85 | AOC3 (0.47) | AOC3PKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114195764-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| WO-2022057845-A1 | COMPOUND SERVING AS THYROID HORMONE β RECEPTOR AGONIST AND USES OF COMPOUND | 广东东阳光药业有限公司 | 2022-03-24 | — | — | WO | disclosed |
| CN-114195764-A | Compound as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396495-B2 | Amine compound for inhibiting SSAO/VAP-1 and use thereof | VCAM1, VAPB, ICAM1 | PDE4A 3611/4885PDE4B 3997/4885PDE4C 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.